Paricalcitol in Treating Patients With Advanced Prostate Cancer and Bone Metastases

Stopped early · Phase 2

Conditions studied: Metastatic Cancer, Prostate Cancer

In brief

RATIONALE: Paricalcitol may help prostate cancer cells become more like normal cells, and to grow and spread more slowly. It may also stop the growth of tumor cells in bone. PURPOSE: This phase II trial is studying how well paricalcitol works in treating patients with advanced prostate cancer and bone metastases.

Key facts

Study ID

NCT00634582

Run by

Wake Forest University Health Sciences

People needed

2

Starts

2009-01-01

Expected to finish

2015-06-01

Last updated by the study team

2018-07-06

Who can join

Age: 18 and older, up to 120. Sex: male. Healthy volunteers: not accepted.

Where it is running

• Wake Forest University Comprehensive Cancer Center — Winston-Salem, North Carolina, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.